Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 10/20 | 0.69 |
| ▸ | HMGCR | P04035 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626035 | 0.94 | SF3B3 (0.65) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23191574 | 0.90 | SF3B3 (0.59) | SF3B3 | |
| SCHEMBL3625445 | 0.90 | SF3B3 (0.61) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3614575 | 0.90 | SF3B3 (0.65) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12394077 | 0.90 | SF3B3 (0.69) | SF3B3 | |
| SCHEMBL29343498 | 0.90 | SF3B3 (0.58) | SF3B3 | |
| SCHEMBL22459921 | 0.90 | SF3B3 (0.58) | SF3B3 | |
| SCHEMBL23191411 | 0.90 | SF3B3 (0.58) | SF3B3 | |
| SCHEMBL14396197 | 0.89 | SF3B3 (0.55) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23463802 | 0.87 | SF3B3 (0.56) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911843-B1 | GENETICALLY MODIFIED MICROORGANISM AND PROCESS FOR PRODUCTION OF MACROLIDE COMPOUND USING THE MICROORGANISM | EISAI R&D MAN CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-8008049-B2 | DNA coding for polypeptide participating in biosynthesis of pladienolide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008049-B2 | DNA coding for polypeptide participating in biosynthesis of pladienolide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090269820-A1 | Dna coding for polypeptide participating in biosynthesis of pladienolide | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090269820-A1 | Dna coding for polypeptide participating in biosynthesis of pladienolide | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1911843-A1 | GENETICALLY MODIFIED MICROORGANISM AND PROCESS FOR PRODUCTION OF MACROLIDE COMPOUND USING THE MICROORGANISM | Eisai R&D Management Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | SANLI HOLDINGS CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | SANLI HOLDINGS CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1770165-A1 | DNA CODING FOR POLYPEPTIDE PARTICIPATING IN BIOSYNTHESIS OF PLADIENOLIDE | Eisai R&D Management Co., Ltd. (JP) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | CYP51A1, DNMT3A, HSD17B10 | SF3B3 2463/4885HMGCR 207/4885MEN1 3554/4885 |
| US-20090269820-A1 | Dna coding for polypeptide participating in biosynthesis of pladienolide | POLL, DNAJC10, PLAAT4 | SF3B3 2602/4885HMGCR 830/4885MEN1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.